{"id":7575,"date":"2025-12-08T08:00:25","date_gmt":"2025-12-08T07:00:25","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=congress-resource&#038;p=7575"},"modified":"2025-12-08T13:57:17","modified_gmt":"2025-12-08T12:57:17","slug":"sequoia-arm-d-3-year-results-of-zanubrutinib-plus-venetoclax-for-tn-cll-sll-with-del17p-and-or-tp53-and-uighv","status":"publish","type":"congress-resource","link":"https:\/\/beonemedaffairs.com\/us\/congress-resource\/7575\/sequoia-arm-d-3-year-results-of-zanubrutinib-plus-venetoclax-for-tn-cll-sll-with-del17p-and-or-tp53-and-uighv\/","title":{"rendered":"Zanubrutinib + venetoclax for treatment-naive chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL), including patients with del(17p) and\/or TP53 mutation and unmutated immunoglobulin heavy-chain variable status: 3 year results from SEQUOIA arm D"},"content":{"rendered":"","protected":false},"template":"","post-tag":[760,704,614,630,673,628,594,781,777,563,595,845,776,542],"class_list":["post-7575","congress-resource","type-congress-resource","status-publish","hentry","post-tag-american-society-of-hematology","post-tag-ash","post-tag-bcl-2-inhibitor","post-tag-bcl2i","post-tag-btk-inhibitor","post-tag-btki","post-tag-chronic-lymphocytic-leukemia","post-tag-cll-sll","post-tag-del17p","post-tag-sequoia","post-tag-small-lymphocytic-lymphoma","post-tag-treatment-naive-cll-sll","post-tag-venetoclax","post-tag-zanubrutinib","congress_resource_type-poster","content_type-reading","disease_state-chronic-lymphocytic-leukemia","disease_state-small-lymphocytic-lymphoma","molecule-zanubrutinib"],"acf":{"congress_resource_url_override":"ash-2025","congress":6819,"category":245,"prioritization":0,"key_data_presentation":true,"key_data_presentation_only":false,"key_data_presentation_prioritization":130,"tags":[704,760,781,594,595,845,777,563,542,628,673,776,630,614],"visible_tags":[704,781,542],"content-type":246,"summary":"","text_app":"&nbsp;\r\n\r\nThis report presents three-year results for zanubrutinib plus venetoclax in newly diagnosed chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) patients, including those with high-risk genetic features. This investigational combination led to high rates of deep remission and durable responses, regardless of genetic risk factors. Most patients remained progression-free, and the safety profile was reported as manageable. The most common grade \u22653 adverse events (AEs) were decreased neutrophil count, hypertension, and diarrhea. These findings may support the use of this regimen for newly diagnosed CLL\/SLL, including those with high-risk features.\r\n\r\n<em>The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and\/or efficacy for such investigational products or uses may be made.<\/em>","text":"&nbsp;\r\n\r\nThis report presents three-year results for zanubrutinib plus venetoclax in newly diagnosed chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) patients, including those with high-risk genetic features. This investigational combination led to high rates of deep remission and durable responses, regardless of genetic risk factors. Most patients remained progression-free, and the safety profile was reported as manageable. The most common grade \u22653 adverse events (AEs) were decreased neutrophil count, hypertension, and diarrhea. These findings may support the use of this regimen for newly diagnosed CLL\/SLL, including those with high-risk features.\r\n\r\n<em>The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and\/or efficacy for such investigational products or uses may be made.<\/em>","table_heading":"","table":null,"faq_heading":"FREQUENTLY ASKED QUESTIONS","faq":null,"button_alt_link":"","no_post_image_preview":true,"download_file_reading":"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/12\/ASH2025_sequoia-arm-d-3-year-results-of-zanubrutinib-plus-venetoclax-for-tn-cll-sll.pdf","display_file_reading":null,"download_file_slidekit":null,"display_file_slidekit":null,"3qsdn":"","webcast":"","vimeo_url":"","videolange":null,"fliphtml_link":"","use_pdf_instead_of_fliphtml":false,"congress_resource_abstract_link":"","congress_resource_cta_label":"See abstract","congress_resource_cta_link":"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/295739","authors":[6580],"field_page_schema_override":[{"field_page_schema_override_type":"PresentationDigitalDocument","field_page_schema_override_data":"{\r\n  \"@type\": \"PresentationDigitalDocument\",\r\n  \"name\": \"Zanubrutinib + venetoclax for treatment-naive chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL), including patients with del(17p) and\/or TP53 mutation and unmutated immunoglobulin heavy-chain variable status: 3 year results from SEQUOIA arm D \u2013 BeOne Medical Affairs | US\", \r\n  \"description\": \"Explore the ASH 2025 poster of SEQUOIA Arm D 3-year results on zanubrutinib + venetoclax in TN CLL\/SLL by Mazyar Shadman et al.\",  \r\n  \"image\": \"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/10\/ASH2025_sequoia-arm-d-3-year-results-of-zanubrutinib-plus-venetoclax-for-tn-cll-sll.jpeg\",\r\n  \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/sequoia-arm-d-3-year-results-of-zanubrutinib-plus-venetoclax-for-tn-cll-sll-with-del17p-and-or-tp53-and-uighv\/\",  \r\n  \"associatedMedia\": {\r\n    \"@type\": \"MediaObject\",\r\n    \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/295739\",\r\n    \"encodingFormat\": \"application\/pdf\"\r\n  },\r\n  \"datePublished\": \"2025-12-08\",  \r\n  \"keywords\": [\"SEQUOIA Arm D combo therapy outcomes\", \"frontline TN CLL 3-year outcomes\", \"phase 3 combination trial in tn cll sll\", \"sequoia clinical trial\", \"sequoia study\"], \r\n  \"genre\": \"Poster\",   \r\n  \"author\": {\r\n    \"@type\": \"Person\",\r\n    \"name\": \"Mazyar Shadman, MD, MPH\"\r\n  },\r\n  \"publisher\": {\r\n    \"@type\": \"Organization\",\r\n    \"name\": \"BeOne Medicines\",\r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/\"\r\n  },\r\n  \"about\": {\r\n    \"@type\": \"MedicalStudy\",\r\n    \"name\": \"Zanubrutinib + venetoclax for treatment-naive chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL), including patients with del(17p) and\/or TP53 mutation and unmutated immunoglobulin heavy-chain variable status: 3 year results from SEQUOIA arm D\",  \r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/sequoia-arm-d-3-year-results-of-zanubrutinib-plus-venetoclax-for-tn-cll-sll-with-del17p-and-or-tp53-and-uighv\/\"\r\n  }\r\n}"},{"field_page_schema_override_type":"MedicalWebPage","field_page_schema_override_data":"{\r\n  \"@type\": \"MedicalWebPage\",   \r\n  \"name\": \"Zanubrutinib + venetoclax for treatment-naive chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL), including patients with del(17p) and\/or TP53 mutation and unmutated immunoglobulin heavy-chain variable status: 3 year results from SEQUOIA arm D \u2013 BeOne Medical Affairs | US\",   \r\n  \"description\": \"Explore the ASH 2025 poster of SEQUOIA Arm D 3-year results on zanubrutinib + venetoclax in TN CLL\/SLL by Mazyar Shadman et al.\",  \r\n  \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/sequoia-arm-d-3-year-results-of-zanubrutinib-plus-venetoclax-for-tn-cll-sll-with-del17p-and-or-tp53-and-uighv\/\", \r\n  \"inLanguage\": \"en-US\",\r\n  \"@logo\": {\r\n    \"@type\": \"ImageObject\",\r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/03\/BGI2404-BeOne-Primary-Logo-RGB-M04-V01-2.svg\"\r\n  }\r\n}"}]},"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress-resource\/7575","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress-resource"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/congress-resource"}],"acf:post":[{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/authors\/6580"},{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress\/6819"}],"acf:term":[{"embeddable":true,"taxonomy":"content_type","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/content_type\/246"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/614"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/630"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/776"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/673"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/628"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/542"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/563"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/777"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/845"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/595"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/594"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/781"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/760"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/704"},{"embeddable":true,"taxonomy":"congress_resource_type","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress_resource_type\/245"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=7575"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=7575"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}